WO2023149769A1 - Composition pour la prévention, l'amélioration ou le traitement de lésions cutanées induites par les uv et procédé de protection de la peau l'utilisant - Google Patents

Composition pour la prévention, l'amélioration ou le traitement de lésions cutanées induites par les uv et procédé de protection de la peau l'utilisant Download PDF

Info

Publication number
WO2023149769A1
WO2023149769A1 PCT/KR2023/001667 KR2023001667W WO2023149769A1 WO 2023149769 A1 WO2023149769 A1 WO 2023149769A1 KR 2023001667 W KR2023001667 W KR 2023001667W WO 2023149769 A1 WO2023149769 A1 WO 2023149769A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
ultraviolet rays
preventing
damage caused
skin damage
Prior art date
Application number
PCT/KR2023/001667
Other languages
English (en)
Korean (ko)
Inventor
전동욱
천동욱
강성훈
Original Assignee
전동욱
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전동욱 filed Critical 전동욱
Priority claimed from KR1020230015633A external-priority patent/KR102593843B1/ko
Publication of WO2023149769A1 publication Critical patent/WO2023149769A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1626—Selenium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/211—Carotene, carotenoids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/704—Vitamin B
    • A23V2250/7046—Vitamin B3 niacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596

Definitions

  • the present invention relates to a composition for preventing, improving or treating skin damage caused by ultraviolet rays and a skin protection method using the same, and more particularly, to prevent, improve or treat various symptoms and diseases that may be caused by ultraviolet rays. It relates to a composition that can be used and a skin protection method using the same.
  • UV Ultraviolet
  • UVA 320-400 nm
  • UVB 290-320 nm
  • UVC 200-290 nm
  • UVA and UVB directly damage DNA or generate reactive oxygen species to accelerate skin aging such as loss of skin elasticity and wrinkle formation.
  • keratinocytes present in the skin epidermis have the expression of aquaporin 3 protein, which transports moisture into the cell when exposed to ultraviolet rays, and hyaluronan synthase 2 (HAS2), an enzyme that produces hyaluronic acid (HA). This decreases and causes skin dryness.
  • aquaporin 3 protein which transports moisture into the cell when exposed to ultraviolet rays
  • HAS2 hyaluronan synthase 2
  • HAS2 hyaluronan synthase 2
  • Ultraviolet rays are an environmental factor that should be noted in that they can cause skin aging as well as skin diseases or exacerbate existing skin diseases. Even the intensity of ultraviolet rays is getting stronger every year, so skin problems and health expenditures are also increasing every year. Representative skin diseases caused by ultraviolet rays include skin cancers such as squamous cell carcinoma and basal cell carcinoma. In general, topical sunscreens are used, but it is practically very difficult to apply sunscreens to all parts of the body exposed to ultraviolet rays every 2 to 3 hours.
  • EP0712630 A2 JBC Cosmetics
  • JBC Cosmetics describes preparations for "oral" administration containing carotenoids, tocopherols, ascorbic acid and selenium. This preparation is intended to prevent browning of the skin and sun allergy (photodermatosis).
  • ⁇ -carotene, ⁇ -carotene and lycopene are used as carotenoids in a daily dose of 60 to 150 mg.
  • One aspect of the present invention is to provide a composition for preventing, improving or treating skin damage caused by ultraviolet rays.
  • Another aspect of the present invention is to provide a method for protecting skin from UV rays.
  • a composition for preventing, improving or treating skin damage caused by ultraviolet rays comprising an extract mixture including a green tea extract, a periwinkle extract and a grape seed extract as an active ingredient.
  • a method for protecting skin from ultraviolet rays comprising orally administering the composition of the present invention before, during, and after exposure to ultraviolet rays.
  • composition for preventing, improving or treating skin damage caused by ultraviolet rays of the present invention can be applied by oral and parenteral routes to prevent and improve skin damage caused by ultraviolet rays as well as to obtain a therapeutic effect for diseases caused or aggravated by ultraviolet rays. there is. Therefore, it is possible to ultimately solve various skin problems caused by ultraviolet rays.
  • FIG 3 shows the results of an Investigator's global assessment (IGA) evaluation.
  • TEWL transepidermal water loss
  • FIG. 8 shows a photograph of a minimal erythema dose measurement, and a related photograph is shown in FIG. 9 .
  • a composition that can ultimately reduce various skin problems caused by ultraviolet rays and a method for protecting the skin from ultraviolet rays using the same are provided.
  • a composition for preventing, improving or treating skin damage caused by ultraviolet rays includes an extract mixture including a green tea extract, a hydrangea extract, and a grape seed extract as an active ingredient.
  • the green tea extract is obtained by extracting green tea leaves using water as an extraction solvent, and may be used in a powder form after drying.
  • the extraction may be carried out at room temperature or hot water extraction, and, if necessary, a concentrated product may be used and then filtered, or the extract may be dried and used in the form of a dry powder.
  • the periwinkle extract is obtained by drying at least some of the whole plant parts of the periwinkle, for example, stems and leaves, and then using water as a solvent at 100 to 150 ° C, more specifically 110 to 130 ° C, for example 121 ° C.
  • the extraction time may be from 1 hour to 12 hours, for example, from 2 hours to 8 hours, or from 4 hours to 6 hours. It can be used, and furthermore, the extract can be dried and used in powder form after drying.
  • Grape seed extract is obtained by pulverizing grape seeds and using water, alcohol or an aqueous alcohol solution as an extraction solvent, and the alcohol may be, for example, ethanol, and, for example, an aqueous ethanol solution may be used as an extraction solvent. Furthermore, the filtered result may be used after performing the concentration step if necessary, and furthermore, the extract may be dried and used in the form of a powder after drying.
  • the effect of preventing, improving or treating skin damage caused by ultraviolet rays is based on the active ingredient, and the extraction mixture contains 20 to 60% by weight of green tea extract and 10 to 30% by weight of saffron extract, based on the total weight of the extraction mixture.
  • the extract mixture may include green tea extract, periwinkle extract and grape seed extract, 1 to 3 parts by weight of green tea extract and 1 to 3 parts by weight of grape seed extract per 1 part by weight of periwinkle extract, for example, green tea extract, periwinkle extract and grape seed extract in a weight ratio of 1 to 3 parts by weight: 1 part by weight: 1 to 3 parts by weight, for example, 2:1:1, 3:1:1, or 1:1:3.
  • the antioxidant effect may be insufficient, and therefore, the effect of preventing, improving or treating skin damage caused by ultraviolet rays, which is the purpose of the present invention, may be reduced.
  • composition of the present invention may include at least one additional component selected from the group consisting of nicotinic acid amide, beta-carotene, vitamins, and selenium, and the vitamin is selected from the group consisting of vitamin C, vitamin D, and vitamin E. It may contain at least one vitamin component.
  • the composition of the present invention may further include nicotinic acid amide, beta-carotene, vitamin D, and selenium, and may further include vitamins C and E.
  • composition of the present invention for example, based on the total composition of 2000mg, 150 to 250 mg of green tea extract, 50 to 150 mg of stingray extract, 50 to 150 mg of grape seed extract, 3 to 20 mg of nicotinic acid amide, 0.1 to 10 mg of beta-carotene , 50 s to 1500 IU of vitamin D and 15 to 60 cmg of selenium, 50 to 150 mg of vitamin C and 2 to 15 mg of vitamin E, together with excipients and/or additives.
  • beta-carotene is not included in an amount exceeding 10 mg to prevent side effects.
  • composition of the present invention may be a composition for oral administration for preventing or improving skin damage, and more specifically, the composition for oral administration is a pharmaceutical composition for oral administration, a health functional food composition, or a health supplement composition. may be
  • the pharmaceutical composition for oral administration for preventing, improving or treating skin damage caused by ultraviolet rays is for preventing skin damage caused by ultraviolet rays, improving skin damage caused by ultraviolet rays, protecting skin from ultraviolet rays, or skin damage caused by or worsening by ultraviolet rays. It may be for the treatment of skin diseases.
  • the skin disease may be at least one skin disease selected from the group consisting of sunlight allergy, photosensitivity dermatitis, skin cancer, lupus, melasma, atopic dermatitis, folliculitis, eczema, and dyspigmentation.
  • a pharmaceutical composition for oral administration for preventing, improving or treating skin damage caused by ultraviolet rays is formulated into at least one solid preparation selected from the group consisting of tablets, pills, powders, granules, and capsules, preventing skin damage caused by ultraviolet rays. , it may be a composition for improvement or treatment.
  • the pharmaceutical composition of the present invention is at least one solid preparation selected from the group consisting of tablets, pills, powders, granules, and capsules according to a conventional method according to the purpose of use or suspension, emulsion, syrup, aerosol, etc.
  • Oral formulations of at least one liquid formulation selected from the group consisting of and the like may be administered through the oral route.
  • Suitable carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, amorphous cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil; and the like.
  • the pharmaceutical composition may further include fillers, anti-coagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, and the like.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the pharmaceutical composition, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. can be formulated by mixing. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. In the present invention, the solid preparation may contain the active ingredient in an amount of 10 to 40% by weight based on the total weight of the solid preparation.
  • Oral liquid formulations include suspensions, solutions for internal use, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included.
  • the pharmaceutical composition of the present invention is administered or applied in a pharmaceutically effective amount to a subject in need of prevention, improvement or treatment of skin damage caused by ultraviolet rays.
  • composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by those skilled in the art. However, since it may increase or decrease according to the route of administration, severity of disease, sex, weight, age, etc., the dosage is not limited to the scope of the present invention in any way.
  • a food containing an extract mixture including green tea extract, periwinkle extract and grape seed extract as an active ingredient is provided.
  • the food of the present invention is a food composition that includes all health functional foods, health supplement foods, etc., and the form of the food composition is not particularly limited, and any food made in any form such as liquid, solid, or other liquid phase is included. intended to be
  • the food composition of the present invention is a food composition such as a functional beverage
  • the food composition may include sweeteners, flavors, physiologically active ingredients, minerals, and the like in addition to the active ingredients.
  • Sweeteners can be used in amounts that give the food a moderately sweet taste, and can be natural or synthetic.
  • a natural sweetener is used, and examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.
  • Flavors may be used to improve taste or aroma, and both natural and synthetic flavors may be used. Preferably, it is the case of using a natural one. In case of using natural ones, in addition to flavor, the purpose of enhancing nutrition can also be combined.
  • a natural flavoring agent it may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, etc., or obtained from green tea leaves, roundworms, bamboo leaves, cinnamon, chrysanthemum leaves, jasmine, and the like.
  • those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo, etc. can be used.
  • Natural flavors can be liquid concentrates or solid extracts. In some cases, synthetic flavors may be used, and synthetic flavors may include esters, alcohols, aldehydes, terpenes, and the like.
  • catechins such as catechin, epicatechin, gallocatechin, and epigallocatechin
  • vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine, and riboflavin
  • minerals include calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium, zinc, and the like.
  • the food composition of the present invention may include a preservative, an emulsifier, an acidulant, a thickener, and the like, if necessary, in addition to the sweetener.
  • a preservative emulsifier
  • an acidulant emulsifier
  • a thickener emulsifier
  • a trace amount means a range of 0.0005% by weight to about 0.5% by weight based on the total weight of the food composition when expressed numerically.
  • Preservatives that may be used include sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid) and the like.
  • emulsifiers examples include gum acacia, carboxymethylcellulose, xanthan gum, pectin, and the like.
  • Acidulants that may be used include acid salt, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, and the like.
  • Such an acidulant may be added to the food composition to have an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to enhancing the taste.
  • thickeners that can be used, suspending agents, sedimentation agents, gel forming agents, bulking agents and the like may be mentioned.
  • the composition may be an external composition for preventing, improving or treating skin damage caused by ultraviolet rays
  • the composition for external application is a cosmetic composition for preventing or improving skin damage caused by ultraviolet rays or skin damage caused by ultraviolet rays
  • It may be a pharmaceutical composition for prevention, improvement or treatment.
  • composition preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Vegetable oils such as propylene glycol, polyethylene glycol, and olive oil may be used as non-aqueous solvents and suspending agents.
  • the cosmetic composition may be prepared in various forms, for example, emulsion, lotion, cream (oil-in-water type, water-in-oil type, multi-phase), solution, suspension (anhydrous and aqueous), It can be formulated into formulations such as anhydrous products (oil and glycol based), gels, masks, packs or powders.
  • composition of the present invention may contain additional ingredients including carriers acceptable in cosmetic formulations and/or other additives commonly formulated in cosmetics, if necessary.
  • acceptable carrier in cosmetic preparation refers to a compound or composition that is already known and used, which can be included in a cosmetic preparation, or a compound or composition to be developed in the future, which does not have toxicity more than the toxicity that the human body can adapt to when in contact with the skin.
  • the carrier may be included in the composition of the present invention in an amount of about 1 wt % to about 99.99 wt %, preferably about 50 wt % to about 99 wt %, based on the total weight of the composition.
  • alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, humectant, viscosity modifier, emulsion, stabilizer, sunscreen, coloring agent, fragrance, antioxidant, plant extract, pH adjuster, pigment, etc. can be exemplified.
  • Compounds or compositions that can be used as alcohols, oils, surfactants, fatty acids, silicone oils, humectants, humectants, viscosity modifiers, emulsions, stabilizers, sunscreens, coloring agents, fragrances, etc. are already known in the art, so those skilled in the art An appropriate corresponding material or composition may be selected and used.
  • a method for protecting the skin from ultraviolet rays includes the composition of the present invention before exposure to ultraviolet rays, during exposure to ultraviolet rays, and after exposure to ultraviolet rays. It includes oral administration. For example, it can be administered orally within 12 hours, for example, 6 hours, 3 hours, 1 hour and 30 minutes before exposure to ultraviolet light, during and / or within 12 hours after exposure to ultraviolet light, for example 6 hours. , can be administered orally within 3 hours, 1 hour and 30 minutes.
  • the oral administration may be oral administration of the composition once to three times a day, but is not limited thereto.
  • composition of the present invention can be specially formulated as an oral formulation, and thus can be usefully used for patients suffering from or at risk of suffering from various skin diseases caused or aggravated by ultraviolet rays, and furthermore, general modern people who are oriented toward skin health It can also be widely applied to people to maintain and prevent skin health caused by ultraviolet rays. In this case, it is possible to provide a skin protection effect against ultraviolet rays even in a situation where it is difficult to use a topical sunscreen.
  • Grape seed extract, green tea extract, and night gate extract were obtained by commercial purchase from Shaanxi Jiahe Phytochem co., Ltd, Anhui Redstar Pharmaceutical Co., Ltd, and Haram, respectively.
  • DPPH (1,1-diphenyl-2-picrylhydrazyl), a stable free radical, exhibits maximum wavelength absorption at 517 nm, and when it meets a substance with antioxidant activity, DPPH is reduced and changes from dark purple to light yellow, and is generally free. The more reactive the molecule with the radical, the more effectively it scavenges the DPPH radical.
  • the DPPH sample was dissolved in methanol to prepare a 0.2 mM solution, and each single sample and mixed sample were prepared by concentration using DMSO. Ascorbic acid dissolved in methanol was used as a positive control, and 50 ⁇ L of each sample and 150 ⁇ L of DPPH solution were mixed in a 96-well plate, followed by reaction at 25 ° C.
  • the absorbance was measured with a microplate reader at 517 nm, and the DPPH scavenging activity was calculated by converting the value obtained by dividing the difference in absorbance between the control group and the experimental group by the absorbance of the control group in percentage, and calculated according to the following formula.
  • DPPH 2,2-diphenyl-1-picrylhydrazyl
  • ABTS+ reagent is dark blue-green and changes to transparent white when it meets substances with antioxidant activity.
  • ABTS is a dark bluish-green compound, and its antioxidant efficacy was measured to the extent that it turned into a transparent white color by scavenging free radicals.
  • Ascorbic acid a positive control, was dissolved in DMSO at a concentration of 50 - 1.5625 ⁇ g/mL, and the results of the experiment are shown in FIG. 2 .
  • ingredient content hyaluronic acid 240mg green tea extract 200mg quinoa extract 100mg grape seed extract 100mg beta carotene 0.12mg vitamin C 100mg vitamin D 100 IU vitamin E 2.73mg nicotinic acid amide 3.76mgNE selenium 20 mcg
  • the tablets of the present invention were continuously taken 2 tablets a day for 4 weeks (Day 2-29).
  • Day 29 a 308nm excimer laser of 150, 200, 250, 300, 350, 400 (mJ/cm 2 ) was irradiated at six locations on the upper right back of the subject, and narrowband UVB was applied to the lower right back at 150, 200, 250, 300, 350, 400 (mJ/cm 2 ) Irradiate 6 places.
  • each evaluation item is evaluated. This evaluation result is referred to as 'Post-MI'.
  • Each evaluation item is 1Investigator's global assessment (IGA) evaluation, 2Transepidermal water loss (TEWL) evaluation, 3Erythema Index (EI), Melanin Index (MI) evaluation, 4 Skin hydration evaluation, 5Minimal erythema dose (MED) evaluation, and 6Safety evaluation.
  • IGA Instruments Global Assessment
  • TEWL Transportepidermal water loss
  • EI Evolution-to-Ema Index
  • MI Melanin Index
  • MED Minimal erythema dose
  • 6Safety evaluation is as follows:
  • IGA was evaluated according to the criteria in Table 2 below. As the primary efficacy evaluation item, the mean value of IGA (the sum of all IGA values in the 12 zones and dividing by 12) is checked.
  • Mexameter ® was placed in close contact with the back, and the average value was calculated after measuring twice, and the results are shown in FIGS. 5 and 6, respectively.
  • FIGS. 5 and 6 show sensor probes in which 16 light sources of three different wavelength bands (green 568 nm, red 660 nm, infrared 880 nm) corresponding to melanin and hemoglobin are arranged in a circle with Mexameter ® It was measured using the erythema index (EI) and the melanin index (MI), which is a pigment index, respectively measured as a result, and the unit at this time is an arbitrary unit aribiturary unit (AU).
  • EI erythema index
  • MI melanin index
  • Corneometer ® In a room with constant temperature (20 ⁇ 24 °C) and humidity (28 ⁇ 38%), Corneometer ® was placed in close contact with the back, and the average value was calculated after measuring twice, and the results are shown in FIG. 7 . More specifically, Corneometer ® is a device for measuring the water content within a depth of 30 to 40 ⁇ m in the stratum corneum, and the resulting 'water content' is shown in FIG. .
  • MED Minimum Erythema Dose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour la prévention, l'amélioration ou le traitement de lésions cutanées provoquées par les rayons ultraviolets, et un procédé de protection de la peau l'utilisant. La composition pour la prévention, l'amélioration ou le traitement de lésions cutanées provoquées par les rayons ultraviolets comprend, en tant que principe actif, un mélange d'extraits comprenant un extrait de thé vert, un extrait de Lespedeza cuneata et un extrait de pépins de raisin.
PCT/KR2023/001667 2022-02-07 2023-02-06 Composition pour la prévention, l'amélioration ou le traitement de lésions cutanées induites par les uv et procédé de protection de la peau l'utilisant WO2023149769A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2022-0015221 2022-02-07
KR20220015221 2022-02-07
KR10-2023-0015633 2023-02-06
KR1020230015633A KR102593843B1 (ko) 2022-02-07 2023-02-06 자외선에 의한 피부 손상 예방, 개선 또는 치료를 위한 조성물 및 이를 이용한 피부보호 방법

Publications (1)

Publication Number Publication Date
WO2023149769A1 true WO2023149769A1 (fr) 2023-08-10

Family

ID=87552643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/001667 WO2023149769A1 (fr) 2022-02-07 2023-02-06 Composition pour la prévention, l'amélioration ou le traitement de lésions cutanées induites par les uv et procédé de protection de la peau l'utilisant

Country Status (2)

Country Link
KR (1) KR20230149773A (fr)
WO (1) WO2023149769A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090034241A (ko) * 2007-10-02 2009-04-07 동국대학교 산학협력단 천연 식물소재 및 한약재의 발효방법, 상기 방법에 의해서제조된 발효물 및 이를 함유하는 약학 조성물, 화장품조성물 및 식품 조성물
KR20090123458A (ko) * 2008-05-28 2009-12-02 주식회사 엘씨에스바이오텍 천연 식물소재 또는 한약재의 발효방법, 상기 방법에의해서 제조된 발효물 및 이를 함유하는 화장료 조성물,식료품 조성물 및 약학 조성물
KR20140123371A (ko) * 2013-04-12 2014-10-22 재단법인 대구테크노파크 야관문lpc 추출물을 함유하는 피부광노화 개선기능성 화장료 조성물
EP3607958A1 (fr) * 2017-04-03 2020-02-12 TCI Co., Ltd. Composition pharmaceutique d'extraits de plantes indiquée pour réduire les lésions causées par la lumière ultraviolette
JP6869974B2 (ja) * 2015-06-19 2021-05-12 グローバル ヘルス ソリューションズ リミテッド ライアビリティ カンパニー 活性成分のためのペトロラタムベースの送達システム

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090034241A (ko) * 2007-10-02 2009-04-07 동국대학교 산학협력단 천연 식물소재 및 한약재의 발효방법, 상기 방법에 의해서제조된 발효물 및 이를 함유하는 약학 조성물, 화장품조성물 및 식품 조성물
KR20090123458A (ko) * 2008-05-28 2009-12-02 주식회사 엘씨에스바이오텍 천연 식물소재 또는 한약재의 발효방법, 상기 방법에의해서 제조된 발효물 및 이를 함유하는 화장료 조성물,식료품 조성물 및 약학 조성물
KR20140123371A (ko) * 2013-04-12 2014-10-22 재단법인 대구테크노파크 야관문lpc 추출물을 함유하는 피부광노화 개선기능성 화장료 조성물
JP6869974B2 (ja) * 2015-06-19 2021-05-12 グローバル ヘルス ソリューションズ リミテッド ライアビリティ カンパニー 活性成分のためのペトロラタムベースの送達システム
EP3607958A1 (fr) * 2017-04-03 2020-02-12 TCI Co., Ltd. Composition pharmaceutique d'extraits de plantes indiquée pour réduire les lésions causées par la lumière ultraviolette

Also Published As

Publication number Publication date
KR20230149773A (ko) 2023-10-27

Similar Documents

Publication Publication Date Title
KR20230117253A (ko) 폴리페놀이 풍부한 아보카도 과육 및/또는 껍질 추출물및 이를 포함한 화장학적, 피부과학적 및 기능식품 조성물
KR20080097487A (ko) 베어바스코사이드 및 루테오린을 포함하는 조합물 또는 식물 추출물 및 색소침착 조절을 위한 화장품 또는 약제학적 조성물에서의 이의 용도
AU2005219032A1 (en) Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia
WO2011122869A2 (fr) Composition cosmétique comprenant du coumestrol ou un extrait de fèves contenant du coumestrol, pour les soins de la peau
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
US20110182835A1 (en) Topical Cosmetic Skin Lightening Compositions and Methods of use Thereof
EP1560561A1 (fr) Procede de protection de la peau contre la deterioration induite par le soleil par l'administration orale d'un extrait de i emblica officinalis /i ( i phyllantus emblica /i )
WO2023149769A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de lésions cutanées induites par les uv et procédé de protection de la peau l'utilisant
KR20160035641A (ko) 플로레틴 술폰산염 및 이를 포함하는 피부 상태 개선용 조성물
WO2022177215A1 (fr) Procédé pour favoriser l'activité antioxydante de feuilles de thé pourpre
WO2020059906A1 (fr) Composition comprenant un extrait de cinnamomum aromaticum, de lonicera japonica, d'elsholtzia ciliata, de schisandra chinensis, d'arctium lappa et de paeonia suffruticosa pour la prévention ou le traitement du vieillissement cutané ou de la dermatite et procédé utilisant celle-ci
KR100371504B1 (ko) 분말 상의 포도 발효액 추출물을 함유하고 미백 및 주름방지 효과를 갖는 화장료 조성물
KR102593843B1 (ko) 자외선에 의한 피부 손상 예방, 개선 또는 치료를 위한 조성물 및 이를 이용한 피부보호 방법
KR102639155B1 (ko) 발레클로린을 포함하는 화장료 조성물
KR20190137329A (ko) 지면패랭이꽃 추출물을 포함하는 항노화용 피부외용제 조성물
KR100829718B1 (ko) 먼나무 추출물을 유효성분으로 포함하는 피부 미백용화장료 조성물
US20050089590A1 (en) Method for protection of skin against sun-induced damage by oral administration of an extract of Emblica officinalis (syn. Phyllanthus emblica)
US11376211B2 (en) Composition for the prevention and treatment of skin damages caused by photo-exposure
KR20120131064A (ko) 아위느타리버섯으로부터 분리된 신규한 엘라스타제 저해제 및 이를 유효성분으로 함유하는 노화 예방 또는 개선용 조성물
JP2000256175A (ja) 化粧料組成物
KR0162282B1 (ko) 대황에서 추출한 스틸벤 유도체를 함유하는 자외선 차단용 화장료 조성물
JPH11335230A (ja) 皮膚外用剤
KR101615900B1 (ko) 커큐마 잔소리자를 유효성분으로 함유하는 피부 노화 방지용 조성물
KR102142931B1 (ko) 붉나무 열매 추출물을 포함하는 피지분비 억제용 조성물
WO2015130131A1 (fr) Infusion de thé sans catéchine et composition la contenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750002

Country of ref document: EP

Kind code of ref document: A1